Advances in sequencing technologies make massive parallel sequencing more feasible and afford testing for other hereditary predisposition genes assigned to high BC risk (TP53, PALB2, PTEN), moderate BC risk (CHEK2, ATM, NF1, NBN), elevated, but imprecise BC risk (CDH1, STK11) and OC risk (MMR genes, RAD51D, BRIP1) [3]. This evidence concerns the gene STK11 and breast cancer.